title: Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis.
abstract: The use of DPP-4 inhibitors in combination with insulin has been proposed as an alternative therapeutic option for poorly controlled type 2 diabetes (T2D) patients. We thus performed a meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and safety of this combination therapy in adult T2D patients. Seven eligible studies involving 3,384 participants were included for the study. The resulting data revealed that the combination therapy of DPP-4 inhibitor and insulin is associated with a modest reduction in HbA1c (-0.52%; 95% CI -0.59 to -0.44), a decrease in 2h-PPG (-1.81 mmol/l; -2.23 to -1.38), and an increase in the proportion of patients reaching the target HbA1c of ≤ 7% (RR 2.24; 95% CI 1.80 to 2.77) without increasing the risk of hypoglycemia (RR 1.04; 0.83 to 1.31) or body weight (-0.11 kg; -0.56 to 0.33), as compared with other anti-diabetic treatments. These results support that this combination therapy could serve as a potential therapeutic strategy that offers an alternative option for patients inadequately controlled on other anti-diabetic agents in clinical practice.
authors.affiliation: The Center for Biomedical Research, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology 1059 Jiefang Ave., Wuhan 430030, China.
authors.forename: Cai
authors.initials: C
authors.lastname: Chen
authors.affiliation: The Center for Biomedical Research, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology 1059 Jiefang Ave., Wuhan 430030, China.
authors.forename: Qilin
authors.initials: Q
authors.lastname: Yu
authors.affiliation: The Center for Biomedical Research, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology 1059 Jiefang Ave., Wuhan 430030, China.
authors.forename: Shu
authors.initials: S
authors.lastname: Zhang
authors.affiliation: The Center for Biomedical Research, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology 1059 Jiefang Ave., Wuhan 430030, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Yang
authors.affiliation: The Center for Biomedical Research, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology 1059 Jiefang Ave., Wuhan 430030, China.
authors.forename: Cong-Yi
authors.initials: CY
authors.lastname: Wang
mesh_terms: D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000097:blood / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D018819:Dipeptidyl Peptidase 4; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; C517652:hemoglobin A1c protein, human; C042807:DPP4 protein, human
keywords: DPP-4 inhibitors; hypoglycemia; insulin; type 2 diabetes; weight gain
references.citation: Lancet. 2008 Mar 29;371(9618):1073-84
references.pmid: 18374840
references.citation: Curr Med Res Opin. 2014 Mar;30(3):431-45
references.pmid: 24106875
references.citation: Diabetes Care. 2002 Dec;25(12):2133-40
references.pmid: 12453950
references.citation: Clin Interv Aging. 2014;9:1963-80
references.pmid: 25429208
references.citation: Stat Med. 2002 Jun 15;21(11):1539-58
references.pmid: 12111919
references.citation: Med Clin North Am. 2004 Jul;88(4):787-835, ix
references.pmid: 15308380
references.citation: Acta Diabetol. 2014 Dec;51(6):1015-23
references.pmid: 25311055
references.citation: Curr Med Res Opin. 2012 Apr;28(4):513-23
references.pmid: 22313154
references.citation: Diabetes Care. 2013 Dec;36(12):3875-81
references.pmid: 24062327
references.citation: Diabetes Care. 2012 Jun;35(6):1364-79
references.pmid: 22517736
references.citation: Endocr Rev. 2007 Apr;28(2):187-218
references.pmid: 17353295
references.citation: Lancet. 2011 Mar 19;377(9770):977-9
references.pmid: 21316097
references.citation: Cell Metab. 2013 Jun 4;17(6):819-37
references.pmid: 23684623
references.citation: Diabetes Obes Metab. 2009 Dec;11(12):1145-52
references.pmid: 19758359
references.citation: Curr Drug Targets. 2014 Jun;15(6):600-21
references.pmid: 24611684
references.citation: Curr Vasc Pharmacol. 2013 Nov;11(6):992-1000
references.pmid: 22724475
references.citation: Vasc Health Risk Manag. 2010;6:541-8
references.pmid: 20730070
references.citation: Int J Clin Pract. 2010 Jul;64(8):1121-9
references.pmid: 20236369
references.citation: Pharmacotherapy. 2010 May;30(5):463-84
references.pmid: 20411998
references.citation: J Diabetes Investig. 2014 Sep;5(5):475-7
references.pmid: 25411611
references.citation: Diabetes Care. 2001 Jul;24(7):1226-32
references.pmid: 11423507
references.citation: Diabetes Obes Metab. 2012 Sep;14(9):795-802
references.pmid: 22443183
references.citation: J Diabetes Investig. 2013 Mar 18;4(2):108-30
references.pmid: 24843641
references.citation: N Engl J Med. 2007 Oct 25;357(17):1716-30
references.pmid: 17890232
references.citation: Diabetes Res Clin Pract. 2008 Sep;81 Suppl 1:S23-30
references.pmid: 18684540
references.citation: Int J Gen Med. 2013 Dec 04;6:877-95
references.pmid: 24403842
references.citation: Lancet. 2006 Nov 11;368(9548):1696-705
references.pmid: 17098089
references.citation: Diabetes Care. 2009 Jan;32(1):193-203
references.pmid: 18945920
references.citation: J Clin Epidemiol. 2001 Oct;54(10):1046-55
references.pmid: 11576817
references.citation: Diabetologia. 2007 Jun;50(6):1148-55
references.pmid: 17387446
references.citation: Int J Obes Relat Metab Disord. 2002 Sep;26 Suppl 3:S18-24
references.pmid: 12174319
references.citation: Control Clin Trials. 1996 Feb;17(1):1-12
references.pmid: 8721797
references.citation: Diabetes Obes Metab. 2007 Mar;9(2):194-205
references.pmid: 17300595
references.citation: JAMA. 1999 Jun 2;281(21):2005-12
references.pmid: 10359389
references.citation: Diabetes Obes Metab. 2010 Feb;12(2):167-77
references.pmid: 20092585
references.citation: Br J Clin Pharmacol. 2012 Jul;74(1):75-85
references.pmid: 22242621
references.citation: Diabetes Obes Metab. 2011 Oct;13(10):939-46
references.pmid: 21672124
references.citation: Diabetes Obes Metab. 2011 Mar;13(3):268-75
references.pmid: 21205123